In many life sciences companies the corona pandemic has triggered developments with tax implications: for example, accelerated digitalization and re-nationalization of supply chains. Our expert Dr. Kai Reusch explains why tax authorities in many countries are interested in digital business models and how a relocation of supply chains affects the transfer pricing system and indirect tax position.